(Alliance News) - Cube Labs Spa announced Friday that it and FTherapeutics, a cluster of Spanish companies providing consulting services for new drug discovery and development, have entered into a strategic collaboration agreement.

Under the agreement, FTherapeutics, along with its cluster companies Synthelia Organics, a provider of medicinal and synthetic chemistry solutions for the pharmaceutical and biotechnology industries, and Nostrum Biodiscovery, a company specializing in artificial intelligence-based biotechnology solutions for drug discovery, will collaborate with Cube Labs to pursue early-stage drug discovery and development projects, according to the note issued by the company.

Cube Labs is flat at EUR1.98 per share.

By Claudia Cavaliere, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Copyright 2024 Alliance News IS Italian Service Ltd. All rights reserved.